Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
171.37
354.85
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MDGL stock under the Base Case scenario is 247.4499 USD. Compared to the current market price of 345.1784 USD, Madrigal Pharmaceuticals Inc is Overvalued by 28%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Madrigal Pharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MDGL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Madrigal Pharmaceuticals Inc
Balance Sheet Decomposition
Madrigal Pharmaceuticals Inc
Current Assets | 1.1B |
Cash & Short-Term Investments | 1.1B |
Other Current Assets | 14.9m |
Non-Current Assets | 8.3m |
PP&E | 3.3m |
Intangibles | 5m |
Current Liabilities | 114.3m |
Accounts Payable | 21.5m |
Accrued Liabilities | 92.8m |
Non-Current Liabilities | 117.2m |
Long-Term Debt | 116.1m |
Other Non-Current Liabilities | 1m |
Earnings Waterfall
Madrigal Pharmaceuticals Inc
Revenue
|
76.8m
USD
|
Cost of Revenue
|
-2.8m
USD
|
Gross Profit
|
74m
USD
|
Operating Expenses
|
-622.1m
USD
|
Operating Income
|
-548.1m
USD
|
Other Expenses
|
29.4m
USD
|
Net Income
|
-518.7m
USD
|
Free Cash Flow Analysis
Madrigal Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Madrigal Pharmaceuticals celebrated a successful third quarter, generating $62 million in net sales for Rezdiffra, a treatment for NASH, with over 6,800 patients currently prescribed. Coverage now extends to more than 80% of commercial lives, ahead of schedule. The company's team, bolstered by new R&D leadership, is excited about the upcoming European launch set for late 2025 and anticipates significant growth in 2025 due to robust demand and successful drug positioning. Strong early performance metrics suggest that Rezdiffra may become the foundational therapy for NASH, with the enrollment of cirrhosis patients completed in recent trials, positioning them for market leadership.
What is Earnings Call?
MDGL Profitability Score
Profitability Due Diligence
Madrigal Pharmaceuticals Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
Madrigal Pharmaceuticals Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
MDGL Solvency Score
Solvency Due Diligence
Madrigal Pharmaceuticals Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Madrigal Pharmaceuticals Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MDGL Price Targets Summary
Madrigal Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for MDGL is 376.244 USD with a low forecast of 156.55 USD and a high forecast of 556.5 USD.
Dividends
Current shareholder yield for MDGL is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
MDGL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in Conshohocken, Pennsylvania and currently employs 71 full-time employees. The company went IPO on 2007-02-06. The firm is focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The firm's product candidate, resmetirom, is a liver-directed, selective thyroid hormone receptor-Ăź (THR-Ăź) agonist developed as a once-daily oral pill to treat a number of disease states, including non-alcoholic steatohepatitis (NASH). NASH is a liver disease that affects people with metabolic diseases, such as obesity and diabetes and non-alcoholic fatty liver disease (NAFLD).
Contact
IPO
Employees
Officers
The intrinsic value of one MDGL stock under the Base Case scenario is 247.4499 USD.
Compared to the current market price of 345.1784 USD, Madrigal Pharmaceuticals Inc is Overvalued by 28%.